Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Free Cash Flow · Q4 FY2024 · quarter ended Dec 2024
Free cash flow turns positive
Q4 FY2024 free cash flow was $1.6M, compared with -$1.33M a year earlier.
Context
- Free cash flow amounted to 69.1% of revenue in FY2025, up 43.6 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (6.74M) USD
- Year-over-year change
- -423.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.74M) | -423.9% |
| FY2024 | 2024-12-31 | 2.08M | +131.6% |
| FY2023 | 2023-12-31 | 898.37K | -79.8% |
| FY2022 | 2022-12-31 | 4.45M | +6.4% |
| FY2021 | 2021-12-31 | 4.18M | — |
Free Cash Flow vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -423.9% is the 9th highest of 10, against a peer median of +7.2%.
- Free cash flow amounts to 69.1% of revenue for NNNN, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $200M USD | -231.6% | — | 0.9% | |
| LTM Mar 2026 | $170.32M USD | -1974.9% | -3.0% | 306.7% | |
| LTM Mar 2026 | $159.52M USD | +10.8% | +14.0% | — | |
| LTM Mar 2026 | $79.27M USD | +124.4% | — | 26.4% | |
| LTM Mar 2026 | CA$52.75M CAD | +7.2% | — | 5.6% | |
| LTM Mar 2026 | $26.7M USD | +127.5% | +14.2% | 65.8% | |
| LTM Dec 2025 | $23.85M USD | — | — | 20.6% | |
| LTM Mar 2026 | $7.5M USD | -93.4% | -15.6% | 1.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $6.74M USD | -423.9% | — | 69.1% |
| LTM Mar 2026 | $6.49M USD | -195.5% | -67.5% | 2.7% | |
| LTM Feb 2026 | $1.5M USD | +105.3% | +8.3% | 0.5% | |
| Peer median (excluding NNNN) | — | +7.2% | +2.7% | 5.6% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.54M | 10.01M | 2.25M | 2.37M | 6.4M |
| Depreciation & Amortization | 0 | 6.25K | 12.06K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.65M | (5.53M) | (1.2M) | 44.65K | (13.21M) |
| Accounts Receivables | (717.5K) | 717.5K | (1.88M) | 820.17K | (2.59M) |
| Inventory | 0 | (353.87K) | 353.87K | 0 | 0 |
| Accounts Payables | 1.89M | (481.82K) | (580.89K) | 798.1K | (1.63M) |
| Other Working Capital | 473.15K | (5.41M) | 907.97K | (1.57M) | (8.99M) |
| Other Non-Cash Items | 1 | (40.87K) | (163.39K) | (337.1K) | 68K |
| Operating Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
| Capital Expenditures | 0 | (3) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (16.09M) | (18.54M) | (35.47M) | (19.42M) |
| Sales of Investments | 0 | 14.56M | 20.27M | 35.8M | 15.22M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (1.53M) | 1.73M | 337.1K | (4.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 7.23M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (42.84K) | (344.61K) | (282.55K) |
| Financing Cash Flow | 0 | 0 | (42.84K) | (344.61K) | 6.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.18M | 2.92M | 2.59M | 2.07M | (3.99M) |
| Free Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.